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Resting B lymphocytes can be stimulated to proliferate and differentiate into 
immunoglobulin  (Ig)-synthesizing  cells by anti-IgM  antibodies  together  with  a 
series of T  cell-derived growth and differentiation factors (1-7). The prolifera- 
tion of anti-IgM-activated  B cells can be stimulated by B cell stimulatory factor 
pl  (BSF-pl) I (formerly designated B cell growth factor) (1, 5-7). Differentiation 
to high rate Ig synthesis depends upon two additional T  cell-derived factors (4). 
One (B 15-TRF), which is required early in the course of the response, is found 
in the supernatant  of the B151K12 T  cell hybridoma line (4,  8), and has been 
partially  purified  by Hamaoka et al.  (9).  The  second factor (EL-TRF),  can  be 
added relatively late in the course of the culture (4), and is found in supernatants 
of EL-4  thymoma  cells  that  have  been  stimulated  with  phorbo!  esters.  The 
observation that EL-TRF activity is found in the pH 4.5 fraction of an isoelectric 
focusing separation, which is close to the pI of interleukin  2 (IL-2) (4,  10), raises 
the question as to whether IL-2 is also a B cell differentiation factor. In previous 
work (4),  we tested affinity-purified human  IL-2 at a concentration of 50 U/ml 
and found that it did not display detectable EL-TRF activity. 1 U of IL-2 activity 
is  defined  as  the  reciprocal  of the  dilution  required  to  cause  half-maximal 
proliferation of the IL-2-dependent T  cell line HT-2. The studies reported here 
indicate that molecularly cloned IL-2, at concentrations of 100 U/ml and above, 
does display definite EL-TRF activity and that IL-2 in EL-4 supernatants accounts 
for a  portion  of the EL-TRF activity of such material.  Furthermore,  we show 
that stimulated B cells bear receptors for IL-2 through which they may respond 
to this lymphokine. A second component in EL-4 supernatant,  with a molecular 
weight  of 32,000  and  lacking  any  IL-2  activity,  also displays strong  EL-TRF 
activity. 
Abbreviations used in this paper:  BSF-p1,  B cell stimulatory factor pl; IL-2, interleukin 2; FCS, 
fetal calf  serum; PMA,  phorbol myristate  acetate; SDS-PAGE,  sodium dodecyl  sulfate-polyacrylamide 
gel electrophoresis; PBS, phosphate-buffered  saline; FACS, fluorescence-activated  cell sorter; ELISA, 
enzyme-linked immunoadsorbent assay; HBSS, Hanks' balanced salt solution; NP-40, Nonidet P-40; 
3  3  FITC, fluorescein  isothiocyanate; [ H]IL-2, [ H]leu,lys-IL-2. 
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Materials and  Methods 
Mice.  BALB/c mice were obtained from The Jackson Laboratory, Bar Harbor, ME 
and used at 8-12 wk of age. 
Reagents.  Affinity-purified goat anti-mouse IgM antibody was prepared as previously 
described (11). Two rat monoclonal antibodies specific for the murine IL-2 receptor were 
used.  3C7  is a rat IgG antibody that can compete with IL-2 for binding to its receptor 
(12), and 7D4 is a rat IgM antibody that does not block the binding of IL-2 to its receptor 
but does inhibit IL-2-dependent T cell proliferation (13). Sequential immunoprecipitation 
studies demonstrated that these two antibodies were reactive with the same molecular 
species and precipitated identical components from the surface of T  cells (12).  Two rat 
monoclonal antibodies, kindly provided to us by J. Davie (Washington University School 
of Medicine, St.  Louis, MO) were used as class-matched controls. 50C1C1  (50C1) is a rat 
IgG anti-DNP antibody and 49C2D6R5 (49C2) is a rat IgM anti-trinitrophenyl antibody. 
MAR  18.5,  a  mouse monoclonal antibody to rat kappa chain (14),  was used in indirect 
fluorescent staining. 
Culture Medium.  RPMI 1640 (Biofluids, Inc., Rockville, MD) supplemented with 10% 
fetal calf serum (FCS),  penicillin (50 t~g/ml),  streptomycin (50 t~g]ml), gentamycin (100 
ug/ml), L-glutamine (2  mM), and  2-mercaptoethanol (5  x  10 -~ M) was used as culture 
medium  in  these  experiments.  In  the  preparation  of EL-4  supernatants,  RPMI  1640 
medium containing 1% FCS, with supplements described above, was used. 
Factor Preparation.  EL-4 supernatant was prepared by culturing a cloned subline of 
EL-4 thymoma cells (2 x  106/ml) with  10 ng/ml of phorbol myristate acetate (PMA) for 
48 h  (15).  Cell-free supernatant  was collected and PMA was removed as described (1). 
Partially purified BSF-pl was obtained from this cell-free supernatant by phenyl-Sepharose 
column chromatography (10).  B 151K 12 supernatant was collected from the cloned T  cell 
hybridoma  of this  designation  (8).  Molecularly  cloned  human  1L-2,  purified  by high 
pressure liquid chromatography, was kindly provided to us by Dr. J. Farrar, Hoffman-La 
Roche, Inc., Nutley,  NJ.  We also received molecularly cloned human  IL-2 from Dr. J. 
Koths, Cetus Corp., Emeryville, CA. The latter preparation was reported to contain 0.67 
fg of endotoxin per unit of IL-2, as defined by assay in our laboratory. 
Gel Filtration.  Cell-free supernatant from induced EL-4 cells was concentrated by an 
Amicon concentrator using a YM 10 membrane (Amicon Corp., Lexington, MA), followed 
by sequential  precipitation with  40 and  90%  ammonium sulfate. The 90%  ammonium 
sulfate precipitate was dissolved in a small volume of Dulbecco's phosphate-buffered saline 
(PBS), dialyzed extensively against the same buffer, and then fractionated by gel filtration 
on  a  Sephadex  G150  column  that  had  been  equilibrated  with  Duibecco's PBS.  Each 
fraction was examined for its BSF-pl, IL-2, and EL-TRF activities. BSF-pl activity was 
tested in a  B cell costimulator assay described elsewhere (1).  IL-2 activity was measured 
by the stimulation of uptake of [SH]thymidine by an IL-2-dependent cell line (HT-2) (16). 
1  U  of 1L-2  is defined as the amount  required  to cause half-maximal uptake of [~H]- 
thymidine by 4 x  l0 s HT-2 cells in the last 4 h of a 28 h culture period. EL-TRF activity 
was determined as described below. 
Sodium Dodecyl Sulfate-Polyacrylamide  Gel Electrophoresis (SDS-PAGE).  Samples (frac- 
tions  52-54)  from Sephadex G150  column  chromatography containing  peak EL-TRF 
activity were further fractionated by slab gel SDS-PAGE (17). The samples were dialyzed 
for  16  h  against  sample buffer that  contained  Tris-HCl (pH  6.8),  1%  SDS,  and  10% 
glycerol. A running buffer system of Tris-glycine, containing 0.1% SDS, pH 8.5 was used. 
The stacking gel contained Tris-HCI (pH 6.8) and 4%  polyacrylamide. The separation 
gel contained Tris-HCl (pH 8.8) and 12.5 % polyacrylamide. After electrophoresis at room 
temperature, the gel was sliced into 2.0-mm-wide fractions. The gel slices were electro- 
eluted,  in  the  presence of 1%  bovine serum albumin.  Samples were dialyzed at room 
temperature against PBS followed by dialysis against 4.0 M urea to remove the SDS. They 
were then dialyzed at 4°C against PBS and finally against RPMI 1640 medium containing 
1% FCS. Each fraction was made sterile by filtration and examined for its BSF-pl, IL-2, 
and EL-TRF activities. 
B Cell Preparation.  We prepared B cells by pretreatment of donor mice with antithy- NAKANISHI ET  AL.  1607 
mocyte serum followed by passage of spleen cells over a Sephadex G10 column and two 
rounds of complement-mediated lysis with monoclonal anti-Thy-1.2 and anti-Lyt-1.2 (18). 
In most experiments, positive selection, by adherence to and elution from plastic dishes 
coated with anti-IgM antibodies (19),  was coupled to this negative selection procedure. 
Flow microfluorometric analysis on a  fluorescence-activated cell sorter (FACS  II; B-D 
FACS  Systems,  Sunnyvale,  CA)  showed  that  the  cell  populations  obtained  by  these 
sequential purification procedures were ~99% surface IgM positive. 
Assay for IgM-Synthesizing Cells.  2 X 105 purified B cells were cultured in flat-bottom, 
96-well  microtiter  plates  (No.  3596;  Costar,  Cambridge,  MA)  in  0.2  ml  of medium 
containing 5 #g/ml of goat anti-IgM and various combinations of factors. The assay for 
EL-TRF activity was performed by culturing B cells with anti-IgM, BSF-pl,  B15-TRF, 
and  fractions  to  be  examined  for  their  EL-TRF  activity.  After  4-5  d  of culture,  a 
quantitative immunoassay for cytoplasmic IgM content was performed by using an enzyme- 
linked immunoadsorbent assay (ELISA) method (20).  Cells in culture plates were washed 
four times with Hanks' balanced salt solution (HBSS). Nonidet P-40 (NP-40) was added 
to each  well  at a  concentration  of 0.25%  to make cell  lysates that  were  used  for the 
detection of cytoplasmic IgM. Two rat monoclonal anti-mouse # heavy chain antibodies 
(Bet-1  and Bet-2) (21)  were used.  Bet-1  was used for coating the microtiter plates and 
biotinylated Bet-2 was used as a second antibody to detect IgM bound to the Bet-l-coated 
plate. After extensive washing of the plates, a  horseradish peroxidase-avidin conjugate 
was added to each well, followed by incubation with substrate. In some cases, the presence 
of cytoplasmic IgM was determined by immunofluoresence as described previously (4). 
RNA  Preparation  from  Resting B  Cells and  Cultured  B  Cells.  After  4  d  of culture, 
multiple wells from each group were combined and the viable cell number was determined 
by using the trypan blue dye exclusion method. Cell number was adjusted to 3 x  106 per 
group. Total RNA was obtained by lysis with 0.5% NP-40 of 3 ×  106 resting B cells that 
had been cultured for 48 h and of 3 x  106 B cells stimulated for 4 d with anti-IgM and T 
cell-derived factors. After cell lysis, total RNA was extracted with cold phenol (twice) and 
chroloform/isoamylalcohol(24:1) (once) sequentially, and then ethanol precipitated. RNA 
was dotted onto nitrocellulose paper, fixed by baking, and then hybridized with a  3~p. 
labeled  cDNA  clone  specific  for  the  secretory  terminal  of  the  #  chain  and  the  3' 
untranslated region immediately following the terminus. This cDNA was subcloned from 
p#l 2; p#l 2 was kindly provided to us by R. Wall (22).  The specificity of the subcloned 
probe is described elsewhere (22a). After washing twice with 0.3 M NaC1/0.03 M trisodium 
citrate (2× SSC) and twice with 0.2x SSC,  the filter was exposed to Kodak XAR-5 x-ray 
film at -70 °C using an intensifying screen. 
Fluorescence  Staining  of B  Cells  Stimulated  with  Anti-IgM  Plus  T  Cell-Derived  Fac- 
tors.  Direct fluorescent staining was performed by incubating the cells (1  x  106) for 30 
min at 4°C  with  1-2 #g of fluorescein-isothiocyanate-conjugated monoclonal antibody. 
After incubation,  cells were washed three times with HBSS containing 0.1%  NaN3 and 
3% FCS,  and then analyzed on a FACS. The capacity of unconjugated 3C7 and 7D4 to 
compete in this binding was also assessed on the FACS; 2 x  105 cells were first incubated 
with  the  supernatants  containing  the  indicated  monoclonal  antibodies  followed by an 
additional  incubation  with  1-2 #g of FITC-conjugated 3C7  or FITC-conjugated  7D4. 
The samples were then  washed and analyzed on the  FACS.  10,000-20,000  cells were 
analyzed for each determination. Dead cells, identified by staining with propidium iodide, 
were excluded from analysis. Indirect fluorescent staining was performed as previously 
described (13)  by incubating  the  cells (1  x  106) with an excess of culture  supernatant 
fluids  containing  the  indicated  monoclonal  antibodies.  After  washing  and  subsequent 
staining with FITC-conjugated MAR 18.5, the samples were analyzed on a FACS. 
Radiolabeled IL-2-bindingAssay.  Biosynthetically radiolabeled [SH]leu,lys-IL-2 ([SH]IL- 
2)  was  prepared  as  described  previously  (23).  The  purification  of  human  IL-2  was 
performed by using affinity chromatography. The eluted  material was comprised of a 
single polypeptide (15,500  mol wt) when analyzed by SDS-PAGE, reverse phase liquid 
chromatography, and amino-terminal amino acid sequence analysis (24). Radiolabeled IL- 
2 binding to whole cells was performed as described in detail previously (23). 1608  IL-2  HAS  B  CELL  DIFFERENTIATION  FACTOR  ACTIVITY 
Results 
A  Portion  of the  EL-TRF Activity  in  EL-4  Supernatants  Co-migrates  with IL-2. 
High rate IgM synthesis by rigorously purified B cells stimulated with anti-IgM 
antibodies depends upon the presence of three T  cell-derived factors: BSF-pl, 
B 15-TRF, and EL-TRF. Omission of any one of these factors leads to a meager 
response but when all three factors are present,  10-30% of the resulting B cells 
contain substantial amounts of cytoplasmic IgM (4). In the experiment illustrated 
in Fig.  1, the total concentration of cytoplasmic IgM in lysates of cells stimulated 
with  all  three  factors  was  2.35  #g/ml,  whereas  stimulation  of cell  with  any 
mixture  of two factors led to concentrations  of cytoplasmic IgM ranging  from 
0.15 to 0.81  ~g/ml. 
In  an  effort  to  characterize  EL-TRF,  we  added  graded  concentrations  of 
ammonium sulfate to supernatants of EL-4 cells and took the material that was 
soluble at 40% ammonium  sulfate but precipitated at 00% ammonium  sulfate. 
This fraction  contained the bulk of the EL-TRF activity. After dialysis against 
PBS, this material was applied to a Sephadex G-150 column. Samples were tested 
for EL-TRF, BSF-pl, and  IL-2 activity (Fig.  2).  EL-TRF activity was found in 
two portions of the chromatogram,  one with an apparent  molecular weight of 
32,000  and  the  other,  16,000.  IL-2  activity  was  equally  distributed  between 
A 
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E 
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H 
IgM  SYNTHESIS  (p.g/ML) 
0.5  1.0  1.5  2.0  2.5 
BSF-p1  B15-TRF  EL-TRF  '  I  I  1  I 
--  --  --  !  0.049  +  0.001 
+  --  --  ~  0.088  -,-  0.012 
--  +  --  ~  0.245 ±  O.006 
--  --  +  i  0.081  ±  0.007 
+  +  --  ~  0.160 ±  0.013 
+  --  +  ~  0.154 ±  0.002 
--  +  +  ~  0.810 ±  0.010 
+  +  +  2.350 ±  0.050 
I  I  I  I  I  I 
FIGURE  1.  Cytoplasmic IgM in stimulated B Cells. B cells prepared by the Leibson technique 
followed by panning were cultured at 2 x  105 cells/well in the presence of 5/*g/ml of anti- 
IgM. Such cells were cultured alone, or with BSF-pl  (a  1:10 dilution of phenyl-Sepharose- 
purified material from EL-4 supernatant, containing 42 U of BSF-p 1/ml), B 15-TRF (equivalent 
to  125%  of supernatant  from BIS1K12 hybridoma cells),  and EL-TRF (5% of an IL-2-rich 
phenyl-Sepharose fraction of EL-4 supernatant,  containing 65 U  of IL-2/ml), either individ- 
ually or in various combinations. Concentrations of cytoplasmic IgM in triplicate cultures was 
measured on the 4th d of culture by an ELISA. NAKANISHI  ET  AL.  1609 
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FIGURE 2.  Gel filtration of EL-TRF.  Induced  EL-4 supernatant,  after ammonium  sulfate 
precipitation (see Materials and Methods), was applied to a Sephadex G-150 column. Individual 
fractions (2 ml) were tested for OD~a0, IL-2, BSF-pl, and EL-TRF activity. The column had 
previously been calibrated with sheep gamma globulin (SGG;  tool wt 155,000),  bovine serum 
albumin (BSA; tool wt 68,000), and ovalbumin (OVA;  mol wt 43,000). 
these two fractions, while the bulk of the BSF-pl activity was found in the lower 
molecular weight fraction. 
Since  the  higher  molecular  weight  peak  had  considerably  more  EL-TRF 
activity than the lower molecular weight peak, we concentrated our attention on 
this material. Fractions 52, 53, and 54, from the higher molecular weight peak, 
were pooled,  concentrated, and  applied  to  a  SDS-polyacrylamide gel (12.5% 
acrylamide). After electrophoresis, EL-TRF, IL-2, and BSF-pl activities in indi- 
vidual gel slices were measured. EL-TRF activity was found in two areas of the 
electropherogram, one corresponding to 32,000 (fraction 13), the other, 16,000 
(fraction 22) (Fig.  3).  We will designate the former material as high molecular 
weight EL-TRF and the latter as low molecular weight EL-TRF. IL-2 and BSF- 
pl  activity were found only in the lower molecular weight fraction. Thus, EL- 
TRF appears to exist in two forms, separable by SDS-PAGE.  One of the two, 
low molecular weight EL-TRF,  co-migrates with IL-2 and BSF-pl;  the other, 
high molecular weight EL-TRF, is well separated from these two factors. 
IL-2 Has EL-TRF Activity.  To further explore the relationship between IL-2 
and EL-TRF, we tested the ability of a monoclonal antibody to the murine IL-2 
receptor to inhibit the differentiative activity of EL-TRF.  3C7 has been shown 
to inhibit the action of IL-2 on activated T  cells, to block the binding of [SH]IL- 
2 to the IL-2 receptor, and to precipitate a molecule of 48,000-62,000  mol wt 
in size from radioiodinated mouse T  cell membranes. The latter is analogous to 
the characteristics of the IL-2  receptor on activated human T  cells (26).  Fur- 
thermore, affinity-purified human  IL-2  blocks the binding of 3C7  to  T  cells. 
This led to the conclusion that 3C7 is specific for the mouse IL-2 receptor and 
that it competes with IL-2 for binding to that receptor (12). Although 3C7 did 
not show any effect on proliferation of B cells stimulated with anti-IgM and BSF- 
pl  (K. Nakanishi and T. Malek, unpublished observations), ascitic fluid contain- 
ing  3C7  showed substantial,  although  incomplete,  inhibition  of the  EL-TRF 
activity of low molecular weight EL-TRF from SDS-PAGE (Table I,  Exp.  1). 
This  fraction  contained  70  U/ml  of IL-2,  as judged  by  the  HT-2  assay.  By 1610  1L-2  HAS  B  CELL  DIFFERENTIATION  FACTOR  ACTIVITY 
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FIGURE 3.  SDS-PAGE of EL-TRF. Fractions 52-54 from Sephadex G-150 gel filtration (see 
Fig. 2) were pooled, concentrated, and applied to a  12.5% polyacry[amide slab gel containing 
1% SDS and electrophoresed for 6 h at a constant voltage of 150 V. Standards used were BSA 
(tool wt 68,000), OVA (mol wt 43,000), a-chymotripsinogen (mol wt 25,700), B-lactoglobulin 
(mol wt  18,400),  and  cytochrome c (mol wt  12,300).  Fractions (2  ml) were  electroeluted, 
dialyzed, and tested for IL-2, BSF-pl, and ELoTRF activity. 
contrast, 3C7 had no inhibitory action on the EL-TRF activity of high molecular 
weight EL-TRF, which had no measurable IL-2 activity. 
This result was confirmed in a second experiment (Table I, Exp. 2) in which 
molecularly cloned human IL-2 was examined for its capacity to mimic EL-TRF 
by causing IgM  synthesis in  B cells cultured with anti-IgM, BSF-pl,  and B15- 
TRF. The differentiative activity of low molecular weight EL-TRF was dimin- 
ished by  76%  by  3C7,  in  comparison  with  the result  obtained with  50C1,  a 
control ascitic fluid.  3C7 caused no inhibition of stimulation of Ig synthesis by 
high molecular weight EL-TRF. Cloned IL-2, obtained from Hoffman-La Roche, 
Inc., at concentrations of 100-1,000  U/ml caused IgM synthesis in the presence 
of anti-IgM,  BSF-pl,  and B15-TRF;  maximum responses required 500  U/ml. 
This  stimulation  was  inhibited  by  3C7;  the  degree of inhibition  was  greatest 
when the lowest concentrations of IL-2 were used. 
In separate experiments, comparable results were obtained with molecularly 
cloned human IL-2 provided to us by Cetus Corporation.  1,000 U of IL-2 were 
required for maximal IgM synthesis with this material. This should contain 0.67 
pg  of endotoxin,  which is  far  too low  to  induce B  cell differentiation in  the 
presence ofanti-IgM (data not shown). This, together with the specific inhibitory 
effect of 3C7  on  IL-2-induced IgM  synthesis, indicates that small amounts of NAKANISHI  ET  AL. 
TABLE  I 
Inhibition of lgM Synthesis by Monoclonal Anti-IL-2 Receptor  Antibody (3C7) 
1611 
B cells cultured with anti-IgM,  BSF-pl, 
and B 15-TRF plus: 
IgM synthesis (ng/ml) 
Ascites used in the cultures: 
Percent suppression" of IgM 
response 
Exp.  1  None 
Nothing  288 4- 16 
High nlol wt EL-TRF (<1 U/ml)'*  1.100 ±  52 
Low tool wt EL-TRF (70 U/ml)  1,649 4- 8 
Exp.  2  None 
Nothing  180 4- 21 
High tool wt EL-TRF (< 1 U/ml)  920 +  13 
Low mol wt EL-TRF (140 U/ml)  1,020 4- 45 
rlL-2 (100 U/ml)  584 ±  20 
rlL-2 (200 U/nil)  1,680 ±  82 
rlL-2 (500 U/ml)  2,280 + 67 
rlL-2 (1,900 U/nil)  2,560 4- 95 
3C7  A 
232 4- 16 
1,410 4- 50  -45.1 
668 4- 18  67.8 
50CI  3C7  A  B 
161  ±  13  172±6 
1,020 ±  120  1,280 4- 40  -49.7  -29.0 
1,1O0  ±  34  400 4- 1O  72.9  75.7 
520 +  35  212 -¢" 52  90.1  88.9 
1,492 ±  100  420 ±  95  83.5  81.4 
2.110 ±  50  1,100 ±  150  55.8  52.4 
2.230 +  150  1,320 :t: 30  51.8  44.5 
Culture conditions  are described in Materials and Methods and in the legend to Fig.  1 
* The degree of suppression  of lgM synthesis was calculated  using the following formula: percent suppression  =  [1 -  (experimental  group - 
background)/(positive control  -  background)]  x  100. (A) In this comparison,  the positive control  was B cells stimulated  with anti-lgM  and 
factors  in  the absence  of any ascites.  (B) In this comparison,  the  positive  control  was B  cells stimulated  with anti-lgM  and  factors  in  the 
presence of 50C 1 ascites (a rat lgG monoclona] anti<linitrophenyl  antibody).  In both cases, background is IgM synthesis of B cells stimulated 
with anti-lgM,  BSF-p 1, and B 15-TRF, without any source of EL-TRF. 
* IL-2 activity in units per milliliter. 
endotoxin  contaminating  molecularly  cloned  preparations  of IL-2  are  not re- 
sponsible for their observed B cell differentiation activity. 
To further test the capacity of IL-2 to act as a B cell differentiation  stimulus, 
we examined the capacity of RNA from such cells to hybridize to a cDNA probe 
specific for the C terminal and the 3' untranslated regions of the secretory form 
of ~ heavy chain mRNA. Resting B cells cultured for 48 h and B cells stimulated 
for  96  h  with  anti-IgM  and  BSF-pl  with  or without  B15-TRF  have relatively 
small amounts of RNA complementary to the cDNA probe (Fig. 4). The addition 
of cloned I L-2 to cultures containing anti-IgM, BSF-p 1, and B 15-TRF caused an 
8-16-fold enhancement in levels of secretory # chain mRNA.  1,000 U/ml of IL- 
2 caused greater enhancement than did  100 U/ml. 
Differentiation  Effects of Adding  Cloned  IL-2  and  High  Molecular  Weight EL- 
TRF.  The finding that two apparently distinct entities in induced EL-4 super- 
natant, IL-2 and a high molecular weight EL-TRF, act as differentiation  factors 
in the induction of high rate IgM synthesis by B cells treated with anti-IgM, BSF- 
p 1, and B 15-TRF, raises the question of the effect of mixing the two factors. To 
study this, we mixed a low concentration (5%) of fraction  13 from SDS-PAGE, 
which  is devoid  of IL-2  activity  and  contains high  molecular weight  EL-TRF, 
with graded concentrations of cloned  IL-2 (Fig.  5). At all concentrations of IL- 
2,  from  31  to  8,000  U/ml,  the addition  of fraction  13  caused a  greater  than 
additive enhancement of the concentration of cytoplasmic IgM in the stimulated 
cell  population.  The  mechanism  underlying  this  synergistic  effect  of IL-2  and 
high  molecular weight  EL-TRF remains to be elucidated.  However,  this effect 
may explain why pH 4.5 fractions of isoelectric focusing (IEF) separations of EL- 
4  supernatant,  which  contained  relatively  small  amounts  of  IL-2  (50  U/ml), 1612  IL-2  HAS  B  CELL  DIFFERENTIATION  FACTOR  ACTIVITY 
FIGURE 4.  Expression of #, mRNA in B cells. Resting B cells were cultured for the times 
indicated with or without stimulants. RNA was extracted and "dotted" as described in Materials 
and Methods. Dots were probed with a s,p subclone of pt~ 12; radioautographs were exposed 
for 40 h  with an  intensifying screen at -70°C.  Percent of cells with cytoplasmic IgM was 
determined by indirect immunofluorescence on fixed cells from replicate cultures.  30 
8000  2000  500  125  31  0  0 
CONCENTRATION  OF  IL-2 (Units/ML) 
* Fr 13d20%) 
FIGURE 5.  IgM synthesis in cultures containing mixtures of IL-2 and high molecular weight 
EL-TRF. B cells were cultured with anti-lgM, BSF-pl, and B15-TRF either with no source of 
EL-TRF, with molecularly cloned 1L-2, with high molecular weight EL-TRF (5% of fraction 
13 from SDS-PAGE), or with mixtures of IL-2 and high molecular weight EL-TRF. Concen- 
trations of cytoplasmic IgM were measured on day 4 of culture by ELISA. 
nonetheless  gave  very  substantial  EL-TRF  activity in  our  initial studies  (4).  In 
addition, this may account  for the much  stronger differentiation activity of the 
high  molecular  weight  fraction  from  Sephadex  G-150.  This  fraction  contains 
both high molecular weight EL-TRF,  and IL-2, presumably in a  dimeric form. 
Expression of IL-2 Receptors  on Activated B  Cells.  If the  B  cells are the  direct 
target  of  IL-2,  then  they  should  express  receptors  for  this  lymphokine.  We 
examined this in two ways. First, we tested the capacity of monoclonal antibodies 
to the T  cell IL-2 receptor  to bind to B  cells; second, we tested biosynthetically 
radiolabeled IL-2 for binding to B  cells. 
B  cells were  stimulated with anti-IgM  and  BSF-pl  with  or without  B15-TRF NAKANISHI  ET  AL.  161 3 
for 2 d. Cells harvested at that time consisted almost exclusively of IgM-bearing 
cells;  no Thy-l-bearing cells were detected (Fig. 6A). This indicates the purity 
of the cell population  used in  these studies.  B  cells stimulated with anti-IgM, 
BSF-pl, and B15-TRF bind small but significant amounts of 3C7 (Fig. 6B) and 
somewhat greater amounts of 7D4 (Fig.  6C). The specificity of this binding is 
shown by its inhibition by preincubation with the homologous unlabeled mono- 
clonal antibody but not by a  monoclonal antibody of the same class that is not 
specific  for  the  IL-2  receptor.  The  greater  fluorescence intensity  of B  cells 
stained with FITC-7D4 may reflect the fact that FITC-7D4 has a higher fluores- 
cein-to-protein ratio than  FITC-3C7  and that it is an  IgM whereas 3C7  is an 
IgG. 
B cells incubated with anti-IgM, BSF-pl, and B15-TRF bind somewhat more 
FITC-3C7 and FITC-7D4 than do B cells incubated with anti-IgM and BSF-pl, 
only (Fig.  7). This suggests that B15-TRF  may slightly enhance the expression 
of IL-2 receptors on activated B cells. 
To  compare  the  expression  of antigens  recognized  by  3C7  and  7D4  on 
stimulated B cells and on cells from an IL-2-dependent T  cell line (HT-2 cells), 
we carried out indirect immunofluorescence studies using FITC-MAR  18.5  to 
detect binding of 3C7 and 7D4.  Fig. 8  illustrates results using B cells cultured 
with anti-IgM, BSF-pl, and B15-TRF for 3 d  and HT-2 cells fed with IL-2 2 d 
previously. We determined the mean fluorescence intensities of HT-2 cells and 
of stimulated B cells stained with 3C7, 7D4, or SP2/O ascitic fluid, followed by 
FITC-MAR 18.5. Using these data, we estimate that HT-2 cells bound 125-fold 
more 3C7 and 56-fold more 7D4 than did B cells stimulated with anti-IgM, BSF- 
pl, and B15-TRF. 
The B cell preparation  used in  the experiment described in  Fig.  6  was also 
tested for its capacity to bind radiolabeled human IL-2. B cells cultured for2 d 
with anti-IgM, BSF-p 1, and B 15-TRF were incubated with various concentrations 
of [3H]IL-2, ranging from 0.31  to 2 nM (Fig. 9). At the highest concentration of 
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FIGURE 6.  Direct immunofluorescence staining of stimulated B cells. Highly purified B cells 
were cultured for 2  d  with anti-IgM, BSF-pl, and B15-TRF.  Cells were harvested, stained, 
and analyzed on a FACS II. (A) Fluorescence histograms of cells stained with rabbit anti-mouse 
IgM (FITC-RalgM) or with monoclonal rat anti-Thy-1 (G7). (B) Fluorescence histograms of 
B cells stained with FITC-3C7. Cells were preincubated with nonfluoresceinated 3C7 or 50C 1. 
Unstained cells are  included as an additional control.  (C)  Fluorescence histograms of cells 
stained  with  FITC-7D4.  Cells  were  preincubated  with  nonfluoresceinated  7D4  or  49C2. 
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FIGURE 7.  Comparisons of 3C7 an 7D4 staining of B cells stimulated with or without B15- 
TRF. Highly purified B cells were cultured for 2 d with anti-IgM and BSF-pl with or without 
B15-TRF. The cells were harvested and stained with FITC-3C7 or 7D4. (A) Comparison of 
cells stained with 3C7. (B) Comparison of cells stained with 7D4. 
[3H]IL-2 used, we also examined binding when  200 nM cold IL-2 was present. 
At a  total  concentration  of 2  nM  [SH]IL-2,  1,500  molecules of [3H]IL-2 were 
bound per B cell.  In the presence of 100-fold molar excess of unlabeled  IL-2, 
this was reduced to 900 molecules per cell, suggesting that ~600 molecules per 
cell of [3H]IL-2 were specifically bound by stimulated  B cells. Similar amounts 
of [~H]IL-2  were bound by B  cells that  had  been cultured  with anti-IgM  plus 
BSF-pl. The binding of [SH]IL-2 to HT-2 cells was also tested in these experi- 
ments.  HT-2 cells expressed 59,000 receptors for IL-2 per cell; the equilibrium 
constant  of the  binding  of IL-2  to  these receptors was 2.1  x  101° M -m  (Ka  = 
0.047  nM).  In these experiments  HT-2 cells bound ~100 times more [~H]IL-2 
than did B cells cultured with anti-IgM,  BSF-pl, and B15-TRF. This multiple is 
quite consistent with that observed for the relative binding of 7D4 and  3C7 by 
the two cell populations.  In addition,  it should be noted that the binding of IL- 
2  to T  cells was close to saturation  at a  free concentration  of IL-2 of 0.5  nM; 
our results suggest that B cell binding continued to increase between 0.9 and  1.9 
nM  of free  IL-2.  However, the  very small  amounts  of IL-2  bound per  B  cell 
make it difficult to determine whether the binding  [~H]IL-2 to B cells resulted 
from a  lower affinity receptor than  that detected in the binding of low concen- 
trations of IL-2 to HT-2 cells. 
Discussion 
We have previously (4) demonstrated  a  role  for  two distinct  differentiation 
factors for the induction  of high  rate  IgM  synthesis by highly purified  B  cells 
cultured  with  anti-IgM  antibodies  and  BSF-p1.  One  of these  is  found  in  the 
supernatant of EL-4 cells that have been induced with phorbol esters (4).  In the 
present studies,  we found that  IL-2, which is present in such supernatants  at a 
relatively  high  concentration,  has  such  EL-TRF  activity.  The  evidence  that 
supports  this  conclusion  is  that  IL-2  and  EL-TRF  activity  co-migrate  on  gel 
filtration  and  that  IL-2  and  low molecular weight  EL-TRF activity co-electro- 
phorese on SDS-PAGE. The activity of low molecular weight EL-TRF is inhibited NAKANISHI  ET  AL.  1615 
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FIGURE 8.  Comparison of immunofluorescence staining by 3C7  and 7D4 of stimulated B 
cells and HT-2 Cells. B cells were cultured for 3 d with anti-IgM, BSF-pl, and B15-TRF. HT- 
2 cells, a  continuously growing IL-2-dependent cell line, were harvested 2 d  after the last 
feeding. Cells were incubated with a control ascitic  fluid (SP2/0) or with ascitic fluid from 
mice  bearing 3C7  or  7D4  hybridomas. Cells were  stained with  FITC-MAR  18.5.  Mean 
fluorescence intensities were calculated and are indicated next to each histogram. (A) Fluores- 
cence histograms of HT-2 cells. (B) Fluorescence histograms of B cells stimulated with anti- 
IgM, BSF-p  1, and B 15-TRF. Relative  staining was calculated  according to the formula: Relative 
staining = (mean fluorescence of HT-2 cells stained with anti-IL-2 receptor and FITC-MAR 
18.5 -  mean fluorescence of cells stained with SP2/0 and FITC-MAR 18.5.)/(mean fluores- 
cence of stimulated B cells stained with anti IL-2 receptor antibody and FITC-MAR 18.5 - 
mean fluorescence of stimulated B cells stained with SP2]0 and FITC-MAR 18.5). For 3C7, 
relative staining is 57.3 -  7.4/5.7 -  5.3 =  125; for 7D4, relative staining is 158.1  -  7.4/8.0 
-  5.3  =  56. 
by  3C7,  a  monoclonal  antibody  to  the  mouse  IL-2  receptor,  and  molecularly 
cloned  IL-2  exhibits  EL-TRF  activity which  can  be  blocked by  3C7.  Not  only 
did  IL-2  prove  to  have  EL-TRF  activity by  measurement  of the  induction  of 
cytoplasmic IgM, it also caused an 8-16-fold  increase in levels of mRNA  for the 
secretory form of #  heavy chains when  used on B cells cocultured with anti-IgM, 
BSF-pl, and  B15-TRF.  An important  observation regarding  the action of IL-2 
as EL-TRF  is that high concentrations (100  U/ml and above) of this lymphokine 
are required  for induction of IgM synthesis. We will discuss this point in greater 
detail below. 
Since we used very highly purified B  cells, it seemed quite likely that IL-2 was 
acting directly upon  B  cells.  However,  IL-2  can  stimulate  activated  T  cells  to 
secrete factors such as BSF-pl (27) and ~,-interferon (28, 29). Thus, the possibility 
must be considered that  IL-2 is acting indirectly, by stimulating residual T  cells 1616  IL-2  HAS  B CELL  DIFFERENTIATION FACTOR  ACTIVITY 
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FmURE  9.  Binding of [SH]IL-2  to HT-2  ceils and B cells stimulated for 2 d  with anti-IgM, 
BSF-pl,  and  BI5-TRF.  Abscissa represents  the  concentration  of free  [3H]IL-2; ordinate 
represents  the number of bound [SH]IL-2 molecules per cell, obtained after correction  for 
nonsaturable binding. Scatchard plot analysis of [SH]IL-2 binding to HT-2 is also presented, 
where bound [SH]IL-2 molecules per cell is plotted  on the abscissa, and the ratio of bound 
[3H]IL-2 molecules over free concentration of [SH]IL-2  is plotted on the ordinate. The binding 
curve of [SH]IL-2 to stimulated B cells is also presented  here by using a different  scale for 
each axis. The number of [SH]IL-2 bound by B cell in the presence or absence of a 100-fold 
excess of unlabeled IL-2, and the net number of [3H]IL-2 molecules per B cell, are presented. 
to  make a  B  cell  differentiation  factor.  Until  cloned  B  cell  lines  or  single-cell 
assays are used, absolute proof that IL-2 acts on B cells will be lacking. However, 
we  have  shown  that  activated  B  cells  express  small  numbers  of  membrane 
molecules that bear epitopes in common with the T  cell IL-2 receptor and that 
activated B cells bind small numbers of IL-2 molecules. Indeed, relatively similar 
multiples are obtained  by comparing numbers of molecules of [~H]IL-2 bound 
by  HT-2  cells and  by stimulated  B  cells with  the  relative binding  of 7D4  and 
3C7 by these two cell populations. Both approaches suggest that HT-2 cells have 
56-125-fold more IL-2 receptors than B cells stimulated with anti-IgM, BSF-pl, 
and B15-TRF. 
The binding of 3C7  and  7D4  to B  cells activated with anti-IgM and  BSF-pl, 
with or without B 15-TRF, is perhaps not surprising.  Mouse B cell blasts induced 
with lipopolysaccbaride have already been  shown  to bind  7D4 (13) and  human 
hairy cell leukemias, which are B cells as judged by Ig gene rearrangement, and 
some  human  lymphoblastoid  cell  lines  have  been  shown  to  possess  the  Tac 
antigen  (30,  31),  which  is an epitope on.the human T  cell IL-2 receptor.  Thus, 
the  action  of IL-2 as  EL-TRF,  its inhibition  by 3C7,  the  presence of the  3C7 
epitope on activated B  cells,  and  the  capacity of activated B  cells to bind  small 
amounts of [3H]IL-2, all are  in  keeping with a  direct action  of IL-2 on  B  cells 
that have been cultured  with anti-IgM, BSF-pl, and B15-TRF. NAKANISHI ET  AL.  1617 
The high  concentrations  of IL-2 required  for EL-TRF activity need further 
consideration. This requirement could be partly explained if it is postulated that 
B or T  cell responses to IL-2 require the binding of IL-2 to a fixed number of 
IL-2  receptors  per  cell.  The  formation  of a  specific number  of IL-2-receptor 
complexes would depend  upon  the free concentrations  of both IL-2 and  IL-2 
receptors.  Thus,  if one cell type bore fewer IL-2 receptors than  a  second cell 
type, a greater concentration  of free IL-2 would be required to cause the latter 
cell to achieve comparable  numbers  of bound receptors.  However, we do not 
believe  such  an  argument  can  completely  explain  the  requirement  for  high 
concentrations of IL-2 to stimulate B cells. First, such an argument assumes that 
both B and T  cell responses require that similar numbers of receptors must be 
occupied. No evidence exists on this point.  Second, the concentrations of IL-2 
required to cause B cell differentiation appear to be in excess of those necessary 
to saturate T  cell receptors for IL-2, even when T  cell IL-2 receptors are present 
at much higher number than B cell IL-2 receptors. We base this on calculations 
of the concentrations of IL-2 required for stimulating  B cell activation and for 
saturating  T  cell IL-2 receptors.  Cantrell  and  Smith  (25) have reported that  1 
U/ml of affinity-purified IL-2 is equivalent to 5.3 ×  10  -l~  M. 2 Thus,  100 U/ml, 
the concentration  of IL-2  required  for effects on B cells cultured at  2  ×  105/ 
well,  would  be  5.3  nM.  Assuming  that  no  substantial  amounts  of  IL-2  are 
consumed in these B cell cultures (consistent with bound/free ratios observed in 
our binding  experiments),  the available amount  of IL-2  should be more than 
sufficient to saturate receptors on HT-2 cells cultured at densities similar to those 
at which the B cells are cultured. In the binding study presented in Fig. 9, a total 
concentration of -0.8 nM of IL-2 essentially saturated the IL-2 receptors of 5 × 
105 HT-2 cells. This result suggests that  the affinity of the B cell receptor for 
IL-2 is lower than that detected on HT-2 cells. The initia ! binding data reported 
in Fig. 9 is consistent with this possibility. Such a difference is reminiscent of the 
affinity of binding sites for macrophage-specific colony-stimulating activity (CSA- 
M) when examined by competitive binding using lineage-specific CSAs. Granu- 
locyte-specific CSA (CSA-G) competes for CSA-M binding  to its receptor,  but 
100-fold  higher  CSA-G  concentrations  are  required  compared  with  those  of 
CSA-M (32). 
The  action  of  IL-2  in  causing  B  cells  to  differentiate  to  high  rate  IgM- 
synthesizing  cells is  dependent  upon  their  treatment  with  B15-TRF.  Without 
B 15-TRF, neither enhancement in levels of mRNA for the secretory form of 
heavy chains nor the presence of cells with cytoplasmic IgM is observed. However, 
B cells cultured with anti-IgM and BSF-p 1, without B 15-TRF, do express epitopes 
recognized by 3C7 and 7D4 and these stimulated B cells can bind small amounts 
of [3H]IL-2. Thus,  the expression of IL-2 receptors on B cells does not appear 
to depend upon the presence of B15-TRF. Fluorescence histograms of binding 
of  3C7  and  7D4  to  B  cells  indicate  that  B15-TRF-treated  B  cells  do  bind 
somewhat more 3C7 and 7D4 than activated B cells not cultured with this factor. 
Whether this modest increase in receptor expression difference accounts for the 
2 In the calculation of specific activity of [SH]IL-2, it should be noted that the unit which Cantrell 
and Smith (25) adopted is equal to 10 of the units used in this work. Thus, their value of I  U/ml = 
5.3 x  10 -l° M leads to 1 U/ml in our system being equal to 5.3 ×  10  -l~ M. 1618  IL-2  HAS  B  CELL  DIFFERENTIATION  FACTOR  ACTIVITY 
differences in responsiveness to IL-2 or whether the action of B1B-TRF as a  B 
cell  differentiation  molecule  is  mediated  through  a  distinct  mechanism,  not 
dependent  in  changes  in  expression  of IL-2  receptors,  cannot  be answered  at 
this time. 
These results also support the concept that  IL-2 is not limited in its function 
to  the  stimulation  of proliferation.  Thus,  its  action  on  B  cells appears  to  be 
principally to cause Ig synthesis. We have not detected evidence that IL-2 drives 
B cell proliferation directly. The possibility that IL-2 causes a terminal round of 
B cell proliferation that may be necessary for Ig synthesis has, however, not been 
excluded. 
Our results also indicate the existence in induced EL-4 supernatants of a high 
molecular  weight  EL-TRF.  This  material,  which  has  an  apparent  molecular 
weight of 32,000 by gel filtration  and SDS-PAGE, lacks both IL-2 and BSF-p1 
activity. Its structure and its relation to other differentiation factors has not yet 
been defined.  However, no interferon  activity was detected in  high  molecular 
weight  EL-TRF  using  as  an  assay interference  of the  infection  of L  cells  by 
vesicular stomatitis virus (T. Hecht, personal communication). Similarly, a sample 
of genetically cloned mouse "r-interferon provided to us by Dr. P. Gray (Genen- 
tech, Inc., So. San Francisco, CA), did not display EL-TRF activity when added 
on the first day of culture. 
The  relative  roles  of  high  molecular  weight  EL-TRF  and  IL-2  as  B  cell 
differentiation  factors  in  vivo  will  need  to  be  carefully  considered.  This  is 
particularly so because the need for very high concentrations of IL-2 to induce 
differentiation to high rate IgM synthesis of B cells activated with anti-IgM, BSF- 
pl, and B15-TRF naturally raises the question of the physiologic significance of 
this process. Since information regarding the local concentrations of IL-2 in the 
immediate vicinity of IL-2-secreting cells in vivo is not yet available, it would be 
premature  to reach a  decision on this  issue.  One must entertain  the possibility 
that  IL-2  is  not a  physiologic  ligand  in  promoting  IgM  secretion,  but  rather, 
another,  as yet unidentified,  activity is responsible for the B cell IgM secretion 
mediated through B cell IL-2-binding sites. 
Summary 
B cells cultured  with anti-IgM,  BSF-pl, and  B15-TRF will  differentiate  into 
high rate IgM-synthesizing cells in the presence of supernatants  from EL-4 cells 
that  have  been  induced  with  phorbol  myristate  acetate.  These  supernatants 
contain two molecular species (EL-TRFs) that have differentiative activity. One 
co-migrates with  interleukin  2  (IL-2) and  its activity is blocked by antibody to 
the IL-2 receptor.  Furthermore,  molecularly cloned IL-2, at concentrations  of 
100  U/mi  or  more,  expresses such  EL-TRF activity.  The  EL-TRF activity of 
cloned IL-2 can also be inhibited  by antibody to the IL-2 receptor.  The other 
material with EL-TRF activity has a molecular weight of ~32,000. This material 
lacks IL-2 activity. Antibody to the IL-2 receptor does not impair its function. 
B cells stimulated with anti-IgM and BSF-p 1, with or without B 15-TRF, express 
determinants that react with two monoclonal antibodies which recognize distinct 
epitopes on the T  cell IL-2 receptor.  These determinants  are present at much 
lower density (~100-fold)  on  stimulated  B  cells  than  on  HT-2  cells,  an  IL-2- NAKANISH1  ET  AL.  1619 
dependent  T  cell line.  Very small amounts of [3H]IL-2 (<1,000  molecules per 
cell) bind to activated B cells. These results indicate that IL-2 binds to a receptor 
on appropriately prepared B cells and causes them to differentiate into high rate 
IgM-synthesizing cells.  The physiologic significance of the  B  cell differentiative 
activity of IL-2 remains to be investigated. 
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